Recent PCAC Meeting on Peptides: What Happened, What It Means, and What It Does Not Mean
On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) met to review seven peptides for potential inclusion on the Section 503A Bulk Drug Substances List. This is the list of substances that licensed compounding pharmacies may use to prepare patient-specific medications under federal law.
Here is a summary of the outcomes, what each peptide is commonly discussed for, and what the votes actually mean going forward.
What the Committee Voted
Recommended for inclusion on the 503A Bulks List:
BPC-157 (free base and acetate) - 8 yes, 6 no, 1 abstention
KPV - 8 yes, 6 no, 1 abstention
TB-500 (thymosin beta-4 fragment) - 8 yes, 6 no, 1 abstention
MOTS-c - 7 yes, 5 no, 2 abstentions
Epitalon - favorable recommendation (narrow majority)
Semax - favorable recommendation (narrow majority)
Recommended against inclusion:
Emideltide (also known as DSIP / delta sleep-inducing peptide) - majority voted against
These were non-binding advisory recommendations.
Overview of the Peptides Reviewed and Their Proposed Uses
Below is a summary of what each peptide is commonly discussed for in clinical and research settings. These are proposed or investigational uses based on preclinical work, limited human data, or traditional interest — not FDA-approved indications.
BPC-157Often studied for tissue repair, wound healing, and gut protection. One of the uses reviewed by the FDA was ulcerative colitis. It has also drawn interest for supporting recovery from soft-tissue injuries and reducing inflammation.
KPVA short peptide fragment of alpha-MSH with anti-inflammatory properties. It has been explored for wound healing and various inflammatory conditions.
TB-500 (Thymosin Beta-4 fragment)Frequently discussed for tissue repair, wound healing, recovery from injury, and supporting flexibility and recovery after musculoskeletal stress.
MOTS-cA mitochondrial-derived peptide. It has been studied for metabolic health, potential support in obesity and insulin sensitivity, bone health (osteoporosis was a reviewed indication), and exercise-related adaptations.
EpitalonA synthetic pineal peptide often associated with sleep regulation and anti-aging research. Insomnia was among the uses the FDA reviewed. Some interest also exists around cellular aging pathways.
SemaxA synthetic peptide with nootropic and neuroprotective interest. The FDA reviewed it in the context of cerebral ischemia, migraine, and trigeminal neuralgia. It has also been explored for cognitive support.
Emideltide (DSIP)Known as delta sleep-inducing peptide. It has been investigated for sleep regulation, stress response, and potential roles in opioid withdrawal and certain sleep disorders. This was the only peptide the committee recommended against including.
Important reminder: None of these peptides are FDA-approved drugs for the uses listed above.
What This Does Mean
An independent advisory committee has formally recommended that six of these peptides be considered for the 503A Bulks List.
This is a meaningful regulatory step. It signals that the majority of voting members believed these substances could meet the criteria for compounding under Section 503A.
The FDA will now review the committee’s recommendations, the scientific record, public comments, and other factors before deciding whether to move forward with formal inclusion.
What This Does Not Mean
It is important to be precise so patients are not misled by online commentary:
These peptides are not FDA-approved drugs. A PCAC recommendation does not equal FDA approval. None of these substances has gone through the full drug-approval process.
They have not been added to the 503A Bulks List yet. The committee’s vote is advisory only. The FDA is not required to follow the recommendation, and formal addition to the list typically requires further regulatory steps (including notice-and-comment rulemaking). This process can take many months.
Compounding is not automatically legal. Until the FDA completes its process and officially places a substance on the 503A list, the prior restrictions generally remain in place for 503A compounding.
Quality and safety standards have not changed overnight. Even if these peptides eventually become compoundable, they will still need to be prepared under applicable pharmacy compounding regulations with appropriate quality controls.
In short: the PCAC meeting was an important milestone, but it is not the final word and does not create immediate legal access.
Our Position at Affinity Whole Health
At Affinity Whole Health, we only offer legal peptides.
We partner exclusively with licensed compounding pharmacies that operate within current FDA and state regulations. We do not source, recommend, or provide peptides from unregulated “research chemical” suppliers or gray-market channels.
We are closely monitoring the FDA’s next steps following the July 2026 PCAC meeting. If and when any of these peptides are formally added to the 503A Bulks List and can be legally compounded under proper standards, we will evaluate them for potential inclusion in our practice using the same rigorous criteria we apply to all therapies: clinical appropriateness, quality, safety monitoring, and individualized patient care.
Until that happens, our offerings remain limited to substances that are currently authorized for compounding.
What Patients Should Do Going Forward
Be cautious of claims that these peptides are now “FDA-approved” or freely available for compounding. That is not accurate.
Continue working with licensed medical providers who prioritize regulatory compliance and patient safety.
Understand that gray-market peptides carry risks related to purity, sterility, dosing accuracy, and lack of medical oversight.
Stay informed through reliable sources. We will share updates as the FDA takes further action.
Looking Ahead
Additional peptides are expected to be reviewed by the PCAC in a future meeting (targeted before the end of February 2027). The regulatory landscape for peptides continues to evolve, and we remain committed to navigating it transparently and responsibly.
If you have questions about current peptide options that are legally available, or about how we approach regenerative and metabolic therapies at Affinity Whole Health, we invite you to schedule a consultation. Our team is here to provide clear, evidence-informed guidance within the bounds of current law and best clinical practice.
Schedule your consultation today!
As of the date of this post, the formal FDA transcript and final meeting minutes had not yet been published. Vote tallies above are based on the public livestream of the meeting and contemporaneous reporting.
This content is for educational purposes only and does not constitute medical advice. None of the peptides discussed are FDA-approved drugs for the uses reviewed by the PCAC. Compounding status depends on formal FDA action, not advisory committee votes alone. Always consult a qualified healthcare provider regarding any therapy. Individual circumstances vary.
Official FDA Sources
FDA Meeting Page (agenda and materials):July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
Meeting Agenda PDF:https://www.fda.gov/media/193771/download